Selected outcomes in 2017

During working and utilization of our large research infrastructure BBMRI.cz were created plenty of unique outcomes. Here we mention some of them:

Bubancová, I., Kovaříková, H., Laco, J., Ruszová, E., Dvořák, O., Palička, V., Chmelařová, M. Next-Generation Sequencing Approach in Methylation Analysis of HNF1B and GATA4 Genes: Searching for Biomarkers in Ovarian Cancer. Int J Mol Sci 2017;18(2):474. doi: 10.3390/ijms18020474. (IF2016: 3,226)
Cuppens, T., Annibali, D., Coosemans, A., Trovik, J., Ter Haar, N., Colas, E., Garcia-Jimenez, A., Van De Vijver, K., Kruitwagen, R.P., Brinkhuis, M., Zikan, M., Dundr, P., Huvila, J., Carpén, O., Haybaeck, J., Moinfar, F., Salvesen, H., Stukan, M., Mestdagh, C., Zweemer, R., Massuger, L., Mallmann, M., Wardelmann, E., Mints, M., Verbist, G., Thomas, D., Gommé, E., Hermans, E., Moerman, P., Bosse, T., Amant, F. Potential targets analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomas, An ENITEC group initiative. Clin Cancer Res 2017;23(5):1274-1285. doi: 10.1158/1078-0432.CCR-16-2149. (IF2016: 9,619; Q1)
Chovanec,, Selingerova, I., Greplova, K., Leisby Antonsen, S., Nalezinska, M., Høgdall, C., Høgdall, E., Søgaard-Andersen, E., Jochumsen, K.M., Fabian, P., Valik, D., Zdrazilova-Dubska, L. Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer. Oncotarget 2017;8(64):108213-108222. doi: 10.18632/oncotarget.22599. (IF2016: 5,168; Q1)
Kovaříková, H., Bubancová, I., Laco, J., Sieglová, K., Vošmiková, H., Vošmik, M., Dundr, P., Němejcová, K., Michálek, J., Palička, V., Chmelařová, M. Deregulation of selected microRNAs in sinonasal carcinoma: Value of miR-21 as prognostic biomarker in sinonasal squamous cell carcinoma. Head Neck 2017;2017(39):2528-2536. doi: 10.1002/hed.24930. (IF2016: 3,376)
Kubeček, O., Laco, J., Špaček,, Petera, J., Kopecký, J., Kubečková, A., Filip, S. The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. Clin Exp Metastasis 2017;34(5):295-307. doi: 10.1007/s10585-017-9856-8. (IF2016: 3,144)
Kudlacek, J., Chvojka, J., Posusta, A., Kovacova, L., Hong, S.B., Weiss, S., Volna, K., Marusic, P., Otahal, J., Jiruska, P. Lacosamide and Levetiracetam Have No Effect on Sharp-Wave Ripple Rate. Front Neurol 2017;8:687. doi: 10.3389/fneur.2017.00687. (IF2016: 3,552)
Lakomy, R., Poprach, A., Bortlicek, Z., Melichar, B., Chloupkova, R., Vyzula, R., Zemanova, M., Kopeckova, K., Svoboda, M., Slaby, O., Kiss, I., Studentova, H., Juracek, J., Fiala, O., Kopecky, J., Finek, J., Dusek, L., Hejduk, K., Buchler, T. Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. BMC Cancer 2017;17(1):880. doi: 10.1186/s12885-017-3901-5. (IF2016: 3,288)
Pichler, M., Stiegelbauer, V., Vychytilova-Faltejskova, P., Ivan, C., Ling, H., Winter, E., Zhang, X., Goblirsch, M., Wulf-Goldenberg, A., Ohtsuka, M., Haybaeck, J., Svoboda, M., Okugawa, Y., Gerger, A., Hoefler, G., Goel, A., Slaby, O., Calin, G.A. Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis. Clin Cancer Res 2017;23(5):1323-1333. doi: 10.1158/1078-0432.CCR-16-0497. (IF2016: 9,619; Q1)
Stiegelbauer, V., Vychytilova-Faltejskova, P., Karbiener, M., Pehserl, A.M., Reicher, A., Resel, M., Heitzer, E., Ivan, C., Bullock, M., Ling, H., Deutsch, A., Wulf-Goldenberg, A., Adiprasito, J.B., Stoeger, H., Haybaeck, J., Svoboda, M., Stotz, M., Hoefler, G., Slaby, O., Calin, G.A., Gerger, A., Pichler, M. miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5. Clin Cancer Res 2017;23(17):5255-5266. doi: 10.1158/1078-0432.CCR-17-0023. (IF2016: 9,619; Q1)
Truxova, I., Hensler, M., Skapa, P., Halaska, M.J., Laco, J., Ryska, A., Spisek, R., Fucikova, J. Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents. Int Rev Cell Mol Biol 2017;330:115-156. doi: 10.1016/bs.ircmb.2016.09.003. (IF2016: 3,856)